SCHEMBL7129154

SCHEMBL7129154

CCN(CC)CCNC(=O)c1cccc2c1C=CS2(O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
KDM4E B2RXH2 3/20 0.55
HPGD P15428 2/20 0.55
SMN1; SMN2 Q16637 3/20 0.48
LMNA P02545 6/20 0.45
TSHR P16473 2/20 0.45
SLC22A1 O15245 2/20 0.45
ACHE P22303 2/20 0.45
SLC22A2 O15244 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP2C19 P33261 1/20 0.45
BLM P54132 3/20 0.44
PMP22 Q01453 1/20 0.44
KCNH2 Q12809 4/20 0.44
CYP2D6 P10635 4/20 0.44
ADRA2A P08913 3/20 0.44
DRD3 P35462 3/20 0.44
DRD2 P14416 2/20 0.44
HTR2B P41595 2/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7129157 0.89 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL7135556 0.87 SMN1; SMN2 (0.49) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL7121765 0.82 GFER (0.55) ALDH1A1HPGDSMN1; SMN2LMNATSHR
SCHEMBL7135004 0.81 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL7135560 0.76 SMN1; SMN2 (0.45) ALDH1A1KDM4ESMN1; SMN2MAPK1POLR1A
SCHEMBL7132174 0.75 SMN1; SMN2 (0.40) ALDH1A1KDM4EHPGDSMN1; SMN2TSHR
SCHEMBL7132975 0.75 PRSS1 (0.37) ALDH1A1KDM4EHPGDTSHRGAA
SCHEMBL7126840 0.74 POLR1A (0.46) ALDH1A1KDM4ECYP2D6CYP2C9POLR1A
SCHEMBL7129128 0.74 TMEM97 (0.54) ALDH1A1KDM4ELMNATSHRSLC22A1
SCHEMBL7128576 0.74 KMT2A (0.55) ALDH1A1KDM4EHPGDLMNACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO ALDH1A1 3159/4885KDM4E 1111/4885HPGD 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.